Immunomodulatory Effects of DMF Treatment on the Peripheral Lymphocyte Compartment: A Focus on Older MS Patients (478)
Fabrizio Giuliani(University of Alberta), Catherine Miller(Biogen (United States)), Yang Mao‐Draayer(University of Michigan), Erin E. Longbrake(Yale University), Derrick Robertson(University of South Florida), Eris Bame(Biogen (United States)), Oksana Mokliatchouk(Biogen (United States)), Amit Bar‐Or(University of Pennsylvania), Diana Xing(Biogen (United States)), Becky Parks(University of Vermont), Chongshu Chen(Alnylam Pharmaceuticals (United States))
Cited by 1
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k